Konakion Mm Paediatric

Phytomenadione, the active ingredient in Konakion Mm Paediatric, is a vitamin K presented as an injectable solution for intravenous use. It treats vitamin K deficiency bleeding in newborns and reverses the anticoagulant effects of warfarin in patients who require rapid restoration of clotting. GNH USA supplies Konakion Mm Paediatric as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Konakion Mm Paediatric provides vitamin K supplementation for conditions affecting the coagulation cascade. - Vitamin K deficiency bleeding in newborns: prevents hemorrhage during the first days of life. - Warfarin anticoagulation reversal: restores normal clotting in patients receiving warfarin therapy. - Prevention of postoperative bleeding in pediatric surgery: ensures adequate coagulation after surgical procedures.

Konakion Mm Paediatric may be associated with several adverse reactions.

Common Side Effects: - Injection site pain: mild discomfort at the site of administration. - Redness or erythema: localized skin irritation. - Transient fever: low‑grade temperature rise shortly after injection.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe bleeding: paradoxical hemorrhage despite vitamin K administration. - Thrombosis or hypotension: abnormal clot formation or sudden drop in blood pressure.

Use of Konakion Mm Paediatric requires careful clinical consideration. - Use only under medical supervision: dosage determined by the prescriber. - Check for known hypersensitivity: avoid in patients allergic to phytomenadione or excipients. - Monitor coagulation parameters: assess PT/INR after administration. - Avoid in severe liver disease: impaired metabolism may affect efficacy. - Do not mix with incompatible IV solutions: ensure compatibility before co‑administration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Phytomenadione can interact with several medications affecting coagulation.

Major Interactions (Avoid): - Warfarin: concurrent use may blunt reversal effect. - Broad‑spectrum antibiotics (e.g., cephalosporins): may reduce vitamin K synthesis. - Other vitamin K preparations: risk of overdose.

Moderate Interactions (Monitor Closely): - Heparin: additive anticoagulant effect may increase bleeding risk. - Oral contraceptives: potential alteration of clotting balance. - Blood products containing vitamin K antagonists: monitor coagulation closely.